MNG1279
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1271 | — | — | 0.798 |
| 2 | MNG516 | — | — | 0.765 |
| 3 | SRR12475165 | — | — | 0.758 |
| 4 | HL60_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.756 |
| 5 | SRR1313096 | — | B | 0.750 |
| 6 | TCGA-94-8491-01A-11R-2326-07 | — | cohortSQ1 | 0.748 |
| 7 | TCGA-CQ-A4CE-01A-11R-A266-07 | — | — | 0.744 |
| 8 | MNG53 | — | — | 0.743 |
| 9 | SRR650171 | — | — | 0.729 |
| 10 | TCGA-ZF-A9R5-01A-12R-A42T-07 | — | — | 0.728 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.236 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.081 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.072 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.071 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.069 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.043 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.018 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.007 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.004 | Idelalisib | — uncovered |